Crinetics Pharmaceuticals Inc (CRNX)
Healthcare
Biotechnology
83.50 $
-0.1%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Crinetics Pharmaceuticals Inc (CRNX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 90.3% of the shares are freely tradable; institutional investors hold 120.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
120.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
90.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
6.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
106Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.89 | 15,759,799 | +10.3 | 03/31/2026 |
| BlackRock Inc | 8.01 | 8,478,815 | +6.1 | 03/31/2026 |
| Farallon Capital Management, L.L.C. | 7.88 | 8,338,098 | +20.3 | 03/31/2026 |
| Wellington Management Company LLP | 7.71 | 8,157,204 | +1.5 | 03/31/2026 |
| Driehaus Capital Management LLC | 6.04 | 6,395,922 | +0.1 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 5.06 | 5,355,496 | +2.5 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.42 | 4,673,935 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.38 | 4,638,511 | +0.0 | 03/31/2026 |
| HHG PLC | 4.27 | 4,520,251 | +1.8 | 03/31/2026 |
| EcoR1 Capital, LLC | 4.05 | 4,288,120 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.